Narrative Science is the leader in automated narrative generation for the enterprise. Powered by artificial intelligence, its Quill™ platform analyzes data from disparate sources, understands what is important to the end user and then automatically generates perfectly written narratives to convey meaning from the data for any intended consumer or business audience, at unlimited scale.

Forbes Earnings Preview: Pfizer

Pfizer reports its second-quarter earnings on Tuesday, July 29, 2014, and the consensus earnings per share estimate is 56 cents per share.

The consensus estimate remains unchanged over the past month, but it has decreased from three months ago when it was 57 cents. Analysts are expecting earnings of $2.25 per share for the fiscal year. Analysts look for revenue to decrease 4% year-over-year to $12.48 billion for the quarter, after being $12.97 billion a year ago. For the year, revenue is projected to roll in at $49.31 billion.

For three quarters in a row, the company has posted declining profit. Net income dropped 83% year-over-year in the most recent quarter. Profit had already been falling in previous quarters: 59% in the fourth quarter and 19% in the third quarter.

Revenue has declined for the third quarter in a row. Revenue in the first quarter fell 12% year-over-year to $11.35 billion. The figure dropped 10% in the fourth quarter and 10% in the third quarter.

The majority of analysts (58%) rate Pfizer as a buy. This compares favorably to the analyst ratings of 10 similar companies, which average 51% buys.

Post Your Comment

Post Your Reply

Forbes writers have the ability to call out member comments they find particularly interesting. Called-out comments are highlighted across the Forbes network. You'll be notified if your comment is called out.